Skip to main content

Mortimer Ian's Form 4 filing

Xenon Pharmaceuticals Inc.XENE · filed Jan 27, 2025

Accession no.
0000950170-25-009388
Filed
Jan 27, 2025
Trade date
Jan 23-27, 2025
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 8 non-derivative transactions and 3 derivative transactions. Open-market sales total $2.21M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mortimer IanCIK 0001619961Director, Officer (PRESIDENT & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 23, 2025Common SharesMOption exerciseAcquired+16,217$17.76+$288,013.9247,519Direct
Jan 23, 2025Common SharesSSaleDisposed−16,217$40.08F2−$649,977.3631,302Direct
Jan 24, 2025Common SharesMOption exerciseAcquired+22,468$17.76+$399,031.6853,770Direct
Jan 24, 2025Common SharesSSaleDisposed−22,468$40.20F3−$903,213.631,302Direct
Jan 27, 2025Common SharesMOption exerciseAcquired+15,166$17.76+$269,348.1646,468Direct
Jan 27, 2025Common SharesSSaleDisposed−15,166$40.46F4−$613,616.3631,302Direct
Jan 27, 2025Common SharesMOption exerciseAcquired+1,149$17.76+$20,406.2432,451Direct
Jan 27, 2025Common SharesSSaleDisposed−1,149$41.07F5−$47,189.4331,302Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 23, 2025Common SharesMOption exerciseDisposed−16,217$0.00$038,783Direct
Jan 24, 2025Common SharesMOption exerciseDisposed−22,468$0.00$016,315Direct
Jan 27, 2025Common SharesMOption exerciseDisposed−16,315$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F3

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.535, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F4

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F5

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $41.01 to $41.145, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)